EPIDERMOLYSIS BULLOSA MEDICAL RESEARCH FOUNDATION (EIN 943130081) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1990

Legal Domicile

Principal Officer

PAUL JOSEPH

Phone

3109949237

Tax Period

2023-09-01 to 2024-08-31

EPIDERMOLYSIS BULLOSA MEDICAL RESEARCH FOUNDATION, founded in 1990, is a small nonprofit that reported $889K in total revenue in fiscal year 2023. Revenue fell 34% from the prior year — a significant decline worth monitoring. The organization ran a surplus of $488K, a strong 55% operating margin.

Mission

TO FUND MEDICAL RESEARCH TO FIND A CURE FOR EPIDERMOLYSIS BULLOSA. EBMRF FUNDS VARIOUS RESEARCH ORGANIZATIONS ACROSS THE UNITED STATES & INTERNATIONALLY FOR CHILDREN'S HEALTH.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $738,108

Program Service Revenue $0

Investment Income $150,668

Other Revenue $0

TOTAL REVENUE $888,776

Expense Breakdown

Grants Paid $344,866

Salaries & Benefits $0

Fundraising Expenses $21,384

Program Expenses $344,866

Other Expenses $55,826

TOTAL EXPENSES $400,692

Year-over-Year Comparison

	2023	2022	Change
Revenue	$888,776	$1,354,120	-0.3%
Expenses	$400,692	$345,807	+0.2%
Net Income	$488,084	$1,008,313	-0.5%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
ANDREA PETT-JOSEPH	PRESIDENT/EXECUTIVE DIRECTOR	5.00	Officer Director	$0	$0	$0
PAUL JOSEPH	CHIEF FINANCIAL OFFICER	4.00	Officer Director	$0	$0	$0
MARC GURVITZ	DIRECTOR	3.00	Director	$0	$0	$0
PERSIA FARDAD-FINN	DIRECTOR	4.00	Director	$0	$0	$0
LYNN ANDERSON	FOUNDER, PRESIDENT EMERITUS	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$888,776	$400,692	$4,182,723	$488,084
2023	$1,354,120	$345,807	$3,859,639	$1,008,313
2022	$389,920	$225,491	$3,800,076	$164,429
2021	$772,726	$1,497,871	$3,863,477	$-725,145
2020	$1,472,350	$1,109,360	$4,614,354	$362,990
2019	$2,502,866	$2,928,321	$2,958,091	$-425,455
2018	$1,025,388	$2,438,522	$7,383,602	$-1,413,134

EPIDERMOLYSIS BULLOSA MEDICAL RESEARCH FOUNDATION